title: Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne.
abstract: BACKGROUND
  Lipohydroxyacid is a lipophilic derivative of salicylic acid with comedolytic properties.
  
  
  OBJECTIVE
  To compare lipohydroxyacid and salicylic acid peels in subjects with comedonal acne.
  
  
  METHODS
  In this split face, randomized study, 20 subjects with comedonal acne received lipohydroxyacid peels on one side of the face, while the other side was treated with salicylic acid peels. A total of six peels at 2-week intervals were performed. Efficacy was evaluated by counting noninflammatory and inflammatory lesions and by performing a global change in acne assessment. Safety was assessed by evaluating adverse events, global tolerance, and the presence of erythema, scaling, and dryness.
  
  
  RESULTS
  There was a statistically significant decrease of 55.6% and 48.5% from baseline to Day 98 in the mean number of noninflammatory lesions for the sides treated with lipohydroxyacid and salicylic acid peels, respectively (P < 0.001). There was no significant difference in the degree of reduction in noninflammatory lesions between the two peels. There was no significant reduction in the number of inflammatory lesions. Both peels were generally very well tolerated.
  
  
  CONCLUSIONS
  This study suggests that lipohydroxyacid peels can be beneficial to subjects with comedonal acne.
authors: Innovaderm Research Inc., 1851 Sherbrooke Street east, Suite 502, Montreal, Quebec, Canada H2K 4L5. alevesque@innovaderm.ca
authors: Annie
authors: A
authors: Levesque
authors: Iltefat
authors: I
authors: Hamzavi
authors: Sophie
authors: S
authors: Seite
authors: André
authors: A
authors: Rougier
authors: Robert
authors: R
authors: Bissonnette
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000328:Adult; D002615:Chemexfoliation / Q000379:methods*; D004890:Erythema / Q000139:chemically induced; D005145:Face; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use*; D008297:Male; D011537:Pruritus / Q000139:chemically induced; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use; D020156:Salicylic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C113468:2-hydroxy-5-octanoylbenzoic acid; D007641:Keratolytic Agents; D012459:Salicylates; D020156:Salicylic Acid